RxDoctor Payments Data

Bradley Fouraker, MD

Ophthalmology · Brandon, FLNPI 1467445866

Payments from drug & device makers

$2,122in general payments, 2019–2025

Across 18 payments — averaging $117.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eyevance Pharmaceuticals LLC$620
  • Bausch & Lomb Americas Inc.$267
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$222
  • Alcon$216
  • Amgen$150
  • Tarsus Pharmaceuticals, Inc.$140
  • plus $508 from 6 others

What the payments were for

  • Speaking & faculty fees$60028%
  • Food & beverage$1,50471%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,122 in reported general payments places this provider in the 50th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$342,789
Medicare patients
75
Services billed
4,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost87$34,351
Loteprednol Etabonate154$32,004
MoxifloxacinMoxifloxacin Hcl405$24,107
AlrexLoteprednol Etabonate56$22,828
RestasisCyclosporine32$20,705
RhopressaNetarsudil Mesylate49$16,103
XiidraLifitegrast20$13,532
ZerviateCetirizine Hcl21$12,356
TobradexTobramycin/Dexamethasone35$11,471
NatacynNatamycin11$8,025
Lotemax SmLoteprednol Etabonate24$7,621
ProlensaBromfenac Sodium14$6,023
Alphagan PBrimonidine Tartrate17$4,980
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$2,399
Vancomycin Hcl274$2,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Alrex, Lotemax Sm, Prolensa$222$68,476248 claims
AbbVieLumigan, Restasis, Alphagan P$123$60,035136 claims
Bausch & Lomb Americas Inc.Xiidra$267$13,53220 claims
Eyevance Pharmaceuticals LLCZerviate$620$12,35621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →